<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422978</url>
  </required_header>
  <id_info>
    <org_study_id>H17-02157</org_study_id>
    <nct_id>NCT03422978</nct_id>
  </id_info>
  <brief_title>The Effects of Dexmedetomidine on Intravenous Anesthetic Requirements for Children Undergoing Dental Procedures</brief_title>
  <acronym>Dexmed-PRS</acronym>
  <official_title>Anesthetic Sparing Effect of Dexmedetomidine During TIVA With Propofol and Remifentanil for Children Undergoing Dental Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to determine the propofol and remifentanil sparing effects of a
      single dose of dexmedetomidine in the dental population. The investigators plan to do this by
      performing a blinded study with 4 test groups (3 experimental and 1 control), using BIS
      monitoring to titrate TIVA infusion to an acceptable depth of anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      To determine an optimal dose of dexmedetomidine for its anesthetic sparing effect, without
      extending post-operative stay.

      Hypothesis:

      The investigators hypothesize that dexmedetomidine will cause a clinically significant
      reduction of 30% in the amount of propofol and remifentanil required to maintain adequate
      depth of anesthesia, as monitored through the Bispectral Index.

      Justification:

      The dose-sparing effect of dexmedetomidine on TIVA requirements and the dose-response
      relationship between dexmedetomidine and TIVA dosing regimens has not been explored in young
      children. This study will have many relevant applications to many areas of pediatric
      anesthesia practice, such as craniofacial and neurosurgery, sedation techniques in diagnostic
      and interventional radiology, out of OR sedation, and in all young children in whom
      minimizing anesthesia exposure is increasingly sought given possible concerns over the long
      term neurocognitive effects of surgery and anesthesia in early life.

      Objectives:

      To investigate the dose-sparing effect on a propofol/remifentanil infusion of bolus doses of
      dexmedetomidine and to characterize the dose-response relationship between dexmedetomidine
      doses and TIVA dose reduction.

      Research Design:

      The investigators propose a randomized, 4-group comparative study to characterize the effects
      of different bolus doses of dexmedetomidine on the infusion requirements of propofol and
      remifentanil. The study-specific interventions will include a bolus of dexmedetomidine (or
      placebo) at induction of anesthesia, and maintenance of anesthesia, titrated to a Bispectral
      index of 50-60, with propofol and remifentanil infusions.

      Statistical Analysis:

      Standard statistical analysis will be undertaken using R Foundation for Statistical
      Computing, Vienna, Austria). Summary data will be tabulated and presented as median (IQR).
      Mean infusion rates of propofol and remifentanil will be compared between groups using
      Wilcoxon signed-rank test, with 95% confidence intervals obtained by the Hodges-Lehmann
      estimator. Dose (in mcg/kg) of additional opioids given in PACU will be tabulated and
      compared using Fisher's exact test. Bonferroni corrections will be applied as appropriate
      whenever multiple comparisons are performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Assessor of sedation scores post-procedure will be blinded to group allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Propofol and remifentanil sparing</measure>
    <time_frame>Through length of procedure, an average of 1.5 hours</time_frame>
    <description>Propofol and remifentanil sparing as measured by time-averaged, total administered doses of propofol (mg/kg) and remifentanil (mcg/kg) compared to the placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Propofol and remifentanil infusion rate reduction</measure>
    <time_frame>Through length of procedure, an average of 1.5 hours</time_frame>
    <description>Change in infusion rates of propofol and remifentanil (in micrograms/kg/min), measured over time compared to the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PACU sedation</measure>
    <time_frame>30min post-procedure</time_frame>
    <description>Sedation will be scored from 0 (alert) to 4 (unarousable) using the University of Michigan sedation score (UMSS) at 10, 20, and 30 minutes post discontinuation of the infusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU pain scores</measure>
    <time_frame>30min post-procedure</time_frame>
    <description>Pain will be scored from 0 (no pain) to 10 (severe pain), using the FLACC pain scale for ages 2-7 and the FACES pain scale for ages 8-10, and total fentanyl doses in mcg/kg given in the Post Anesthetic Care Unit will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Anesthetic Sparing</condition>
  <arm_group>
    <arm_group_label>Saline bolus</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>10mL normal saline solution administered intravenously over 60 seconds starting after intubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.25 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.50 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.50 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 1.00 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.00 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Single dose dexmedetomidine administered over 60 seconds post-induction.</description>
    <arm_group_label>Dexmedetomidine 0.25 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.50 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 1.00 mcg/kg</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Single dose normal saline administered over 60 seconds post-induction.</description>
    <arm_group_label>Saline bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA 1-2

          -  Elective dental surgery

          -  Planned general anesthesia with TIVA

          -  Age 2-10 years

        Exclusion Criteria:

          -  General anesthesia with inhalation induction

          -  Documented seizure disorder

          -  Cardiac disease

          -  Cardiac rhythm abnormalities

          -  Chronic hypertension

          -  Weight &lt; 5th centile or &gt; 95th centile for age

          -  Pre-operative administration of anxiolytics (such as benzodiazepines or opioid
             analgesics)

          -  Hypersensitivity to dexmedetomidine or any other study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Whyte, MBBS, FRCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>BC Children's Hospital, Department of Anesthesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Poznikoff, BSc</last_name>
    <phone>604-875-2000</phone>
    <phone_ext>1989</phone_ext>
    <email>andrew.poznikoff@cw.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simon Whyte, MBBS, FRCA</last_name>
    <phone>604-875-2711</phone>
    <email>swhyte@cw.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BC Children's Hospital - Department of Anesthesia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Poznikoff, BSc</last_name>
      <phone>604-875-2000</phone>
      <phone_ext>1989</phone_ext>
      <email>andrew.poznikoff@cw.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Simon Whyte, MBBS, FRCA</last_name>
      <phone>604-875-2711</phone>
      <email>swhyte@cw.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Whyte, FRCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randa Ridgway, FRCA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Gorges, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Poznikoff, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://part.bcchr.ca/</url>
    <description>Pediatric Anesthesia Research Team website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Simon Whyte</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

